Correspondence 0001104659-24-059859 from Bio Green Med Solution, Inc. (BGMS)
Bio Green Med Solution, Inc.
Date: May 10, 2024 · CIK: 0001130166 · Accession: 0001104659-24-059859
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-279157
Letter
CYCLACEL PHARMACEUTICALS, INC.
200 CONNELL DRIVE, SUITE 1500
BERKELEY HEIGHTS, NJ 07922
May 10, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Tamika Sheppard
Re: Cyclacel Pharmaceuticals, Inc.
Registration Statement on Form S-1
File No. 333-279157 (the “Registration Statement”)
Acceleration Request
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, Cyclacel Pharmaceuticals, Inc. (the “Registrant”) hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement to Monday, May 13, 2024, at 4:00 p.m. Eastern Time, or as soon as thereafter practicable, or at such other time as the Registrant or its outside counsel, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., request by telephone that such Registration Statement be declared effective.
The cooperation of the staff in meeting the timetable described above is very much appreciated.
Please contact Jeffrey Schultz of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (212) 692-6732, with any questions regarding this request.
Very truly yours,
CYCLACEL PHARMACEUTICALS, INC.
Show Raw Text
CORRESP
1
filename1.htm
CYCLACEL PHARMACEUTICALS, INC.
200 CONNELL DRIVE, SUITE 1500
BERKELEY HEIGHTS, NJ 07922
May 10, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Tamika Sheppard
Re: Cyclacel Pharmaceuticals, Inc.
Registration Statement on Form S-1
File No. 333-279157 (the “Registration
Statement”)
Acceleration Request
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C promulgated under the Securities
Act of 1933, as amended, Cyclacel Pharmaceuticals, Inc. (the “Registrant”) hereby respectfully requests that the Securities
and Exchange Commission accelerate the effective date of the above-referenced Registration Statement to Monday, May 13, 2024, at 4:00
p.m. Eastern Time, or as soon as thereafter practicable, or at such other time as the Registrant or its outside counsel, Mintz, Levin,
Cohn, Ferris, Glovsky and Popeo, P.C., request by telephone that such Registration Statement be declared effective.
The cooperation of the staff in meeting the timetable described above
is very much appreciated.
Please contact Jeffrey Schultz of Mintz, Levin, Cohn, Ferris, Glovsky
and Popeo, P.C., counsel to the Registrant, at (212) 692-6732, with any questions regarding this request.
Very truly yours,
CYCLACEL PHARMACEUTICALS, INC.
/s/ Paul McBarron
Executive Vice President-Finance, Chief Financial Officer and Chief Operating Officer
cc: Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Jeffrey Schultz, Esq.